drugset / Trial / NCT03242551

Biomarkers Investigation of Neoadjuvant Chemotherapy for Breast Cancer

NCT03242551 ↗

Phase 2 Unknown 120 enrolled Shenzhen People's Hospital
SequentialOpen-labelTreatment

Summary

The BINC-B trial is a diagnostic and interventional study in which various function imaging methods as Magnetic Resonance Imaging (PWI, DWI and DCE-MRI) and will be compared with common imaging methods (mammography and/or ultrasound) to investigate if an early response to a combined neoadjuvant chemotherapy in operable or potentially operable breast cancer. For breast cancer patients with positive HER-2, additional Herceptin could improve the response further. In this study the efficacy of combined neoadjuvant therapy with or without Herceptin should be evaluated and the role in predicting the tumor response with different imaging should be estimated.

Timeline

Start
2017-11-08
Primary completion
2022-08-31
Completion
2022-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Trastuzumab Monoclonal antibody 4 mg/kg —
Background Epirubicin Small molecule 100 mg/m2 —
Background Paclitaxel Small molecule 175 mg/m2 —
Background cyclophosphamine Unknown 600 mg/m2 —

Indications